• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2022年中国梧州结核病的临床特征与基因组流行病学调查

Clinical characteristics and genomic epidemiological survey of tuberculosis in Wuzhou, China, 2022.

作者信息

Li Jianpeng, Zhao Manman, Huang Weidao, Huang Xuanxuan, Ou Yongqiang

机构信息

Wuzhou Third People's Hospital, Wuzhou, Guangxi, China.

Medical School, Shenzhen University, Shenzhen, Guangdong, China.

出版信息

Microbiol Spectr. 2025 May 6;13(5):e0247424. doi: 10.1128/spectrum.02474-24. Epub 2025 Apr 10.

DOI:10.1128/spectrum.02474-24
PMID:40207933
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12054142/
Abstract

Tuberculosis (TB) is a serious respiratory disease posing significant public health threats, such as the variation in () lineages and their associated drug resistance across regions. In 2022, clinical data and culture-positive TB samples were collected from the Third People's Hospital in Wuzhou, China. drug resistance and lineage were analyzed using whole-genome sequencing, while logistic regression was applied to identify factors influencing patient outcomes. Among 169 strains analyzed, an overall drug resistance rate of 23.1% was observed. Multidrug-resistant or rifampicin-resistant cases constituted 7.7% of the strains. Most strains belonged to lineage 2 (69.8%), followed by lineage 4 (27.8%). Poor treatment adherence, being aged 65 or older, and retreatment emerged as risk factors for unfavorable outcomes. This pioneering survey provides crucial insights into TB patient characteristics, drug resistance patterns, and lineage distribution in Wuzhou, laying a foundation for future targeted TB control strategies in the region.IMPORTANCEIn 2022, tuberculosis (TB) was the second leading cause of death from a single infectious agent worldwide, posing a serious threat to global health. The epidemiological characteristics of TB vary considerably from country to country, and even from region to region within a single country, due to differences in the economy, medical conditions, education, and other factors. Understanding the current status of TB epidemics in the region is important, with practical implications for local diagnosis, treatment, and control. This genomic epidemiological survey has provided a first insight into the characteristics of TB patients, drug resistance rates, prevalence lineage, and factors associated with unfavorable outcomes in Wuzhou, China.

摘要

结核病(TB)是一种严重的呼吸道疾病,对公众健康构成重大威胁,例如不同地区结核分枝杆菌谱系的差异及其相关耐药性。2022年,从中国梧州第三人民医院收集了临床数据和培养阳性的结核病样本。使用全基因组测序分析耐药性和谱系,同时应用逻辑回归来确定影响患者预后的因素。在分析的169株菌株中,观察到总体耐药率为23.1%。耐多药或耐利福平病例占菌株的7.7%。大多数菌株属于谱系2(69.8%),其次是谱系4(27.8%)。治疗依从性差、年龄在65岁及以上以及再次治疗是不良预后的危险因素。这项开创性的调查为梧州结核病患者特征、耐药模式和谱系分布提供了关键见解,为该地区未来有针对性的结核病控制策略奠定了基础。重要性2022年,结核病是全球单一传染病导致死亡的第二大原因,对全球健康构成严重威胁。由于经济、医疗条件、教育等因素的差异,结核病的流行病学特征在不同国家之间,甚至在一个国家内的不同地区之间都有很大差异。了解该地区结核病流行的现状很重要,对当地的诊断、治疗和控制具有实际意义。这项基因组流行病学调查首次深入了解了中国梧州结核病患者的特征、耐药率、流行谱系以及与不良预后相关的因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97a0/12054142/65d243ceac75/spectrum.02474-24.f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97a0/12054142/65d243ceac75/spectrum.02474-24.f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97a0/12054142/65d243ceac75/spectrum.02474-24.f001.jpg

相似文献

1
Clinical characteristics and genomic epidemiological survey of tuberculosis in Wuzhou, China, 2022.2022年中国梧州结核病的临床特征与基因组流行病学调查
Microbiol Spectr. 2025 May 6;13(5):e0247424. doi: 10.1128/spectrum.02474-24. Epub 2025 Apr 10.
2
Drug-resistance characteristics, genetic diversity, and transmission dynamics of multidrug-resistant or rifampicin-resistant Mycobacterium tuberculosis from 2019 to 2021 in Sichuan, China.2019 年至 2021 年中国四川耐多药或利福平耐药结核分枝杆菌的耐药特征、遗传多样性和传播动态。
Antimicrob Resist Infect Control. 2024 Oct 14;13(1):125. doi: 10.1186/s13756-024-01482-6.
3
Cross-sectional Whole-genome Sequencing and Epidemiological Study of Multidrug-resistant Mycobacterium tuberculosis in China.中国耐多药结核分枝杆菌的横断面全基因组测序和流行病学研究。
Clin Infect Dis. 2019 Jul 18;69(3):405-413. doi: 10.1093/cid/ciy883.
4
Drug-Resistant Characteristics, Genetic Diversity, and Transmission Dynamics of Rifampicin-Resistant Mycobacterium tuberculosis in Hunan, China, Revealed by Whole-Genome Sequencing.中国湖南利福平耐药结核分枝杆菌的耐药特征、遗传多样性和传播动态的全基因组测序研究
Microbiol Spectr. 2022 Feb 23;10(1):e0154321. doi: 10.1128/spectrum.01543-21. Epub 2022 Feb 16.
5
Whole genome sequencing of drug resistant Mycobacterium tuberculosis isolates from a high burden tuberculosis region of North West Pakistan.对来自巴基斯坦西北部高负担结核病地区的耐药结核分枝杆菌分离株进行全基因组测序。
Sci Rep. 2019 Oct 18;9(1):14996. doi: 10.1038/s41598-019-51562-6.
6
Whole-genome sequencing reveals transmission pattern and drug resistance of intra- or inter-hosts.全基因组测序揭示了宿主内或宿主间的传播模式和耐药性。
Front Cell Infect Microbiol. 2025 Jan 21;14:1488547. doi: 10.3389/fcimb.2024.1488547. eCollection 2024.
7
Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases.对印度结核患者临床分离株进行全基因组测序:真实世界数据显示存在较高比例的预广泛耐药病例。
Microbiol Spectr. 2024 May 2;12(5):e0277023. doi: 10.1128/spectrum.02770-23. Epub 2024 Apr 10.
8
Diversified lineages and drug-resistance profiles of clinical isolates of complex in Malaysia.马来西亚复杂临床分离株的多样化谱系和耐药性特征。
Int J Mycobacteriol. 2019 Oct-Dec;8(4):320-328. doi: 10.4103/ijmy.ijmy_144_19.
9
Correlations between drug resistance of Beijing/W lineage clinical isolates of Mycobacterium tuberculosis and sublineages: a 2009-2013 prospective study in Xinjiang province, China.结核分枝杆菌北京/W 家族临床分离株耐药性与亚家族之间的相关性:2009 - 2013年中国新疆前瞻性研究
Med Sci Monit. 2015 May 7;21:1313-8. doi: 10.12659/MSM.892951.
10
Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013.2007 年至 2013 年中国耐多药结核分枝杆菌分离株中莫西沙星耐药率的大幅增加。
Microbiol Spectr. 2021 Dec 22;9(3):e0040921. doi: 10.1128/Spectrum.00409-21. Epub 2021 Dec 1.

本文引用的文献

1
Quinolone Antibiotics: Resistance and Therapy.喹诺酮类抗生素:耐药性与治疗
Infect Drug Resist. 2023 Feb 10;16:811-820. doi: 10.2147/IDR.S401663. eCollection 2023.
2
Drug Resistance of Based on Whole-Genome Sequencing in the Yi Ethnic Group, Sichuan Province, China.中国四川省彝族人群基于全基因组测序的耐药性研究。
J Immunol Res. 2023 Jan 23;2023:4431209. doi: 10.1155/2023/4431209. eCollection 2023.
3
SAM-TB: a whole genome sequencing data analysis website for detection of Mycobacterium tuberculosis drug resistance and transmission.
SAM-TB:一个用于检测结核分枝杆菌药物耐药性和传播的全基因组测序数据分析网站。
Brief Bioinform. 2022 Mar 10;23(2). doi: 10.1093/bib/bbac030.
4
A genome epidemiological study of mycobacterium tuberculosis in subpopulations with high and low incidence rate in Guangxi, South China.中国华南广西地区高、低发病率人群结核分枝杆菌的基因组流行病学研究。
BMC Infect Dis. 2021 Aug 19;21(1):840. doi: 10.1186/s12879-021-06385-0.
5
Rational use of the fluoroquinolones.氟喹诺酮类药物的合理使用。
S Afr Med J. 2019 May 31;109(6):378-381. doi: 10.7196/SAMJ.2019.v109i6.14002.
6
Spatiotemporal patterns and ecological factors of tuberculosis notification: A spatial panel data analysis in Guangxi, China.肺结核报告的时空模式和生态因素:中国广西的空间面板数据分析。
PLoS One. 2019 May 2;14(5):e0212051. doi: 10.1371/journal.pone.0212051. eCollection 2019.
7
The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019.氟喹诺酮类药物在 2019 年结核病治疗中的作用。
Drugs. 2019 Feb;79(2):161-171. doi: 10.1007/s40265-018-1043-y.
8
Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Hunan, China.中国湖南耐药结核分枝杆菌的流行情况及分子特征
Antimicrob Agents Chemother. 2014 Jun;58(6):3475-80. doi: 10.1128/AAC.02426-14. Epub 2014 Apr 14.
9
Anti-tuberculosis drug resistance patterns and trends in a tuberculosis referral hospital, 1997-2009.1997-2009 年结核病转诊医院的抗结核药物耐药模式和趋势。
Epidemiol Infect. 2011 Dec;139(12):1909-18. doi: 10.1017/S0950268810003158. Epub 2011 Jan 27.
10
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.耐多药和广泛耐药结核病的最佳药物治疗。
Lancet Infect Dis. 2010 Sep;10(9):621-9. doi: 10.1016/S1473-3099(10)70139-0.